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Abstract
Raltegravir (RAL) is the only licensed human immunodeﬁciency virus (HIV) integrase inhibitor. The factors associated with the virological
response to RAL-containing regimens and the prevalence of integrase mutations associated with RAL failure deserve further investigation.
From the Antiretroviral Resistance Cohort Analysis database, we selected triple-class-experienced subjects failing their current treatment
with complete treatment history available. Selection criteria included HIV-RNA, CD4 count and HIV genotype within 3 months of RAL
initiation. Factors associated with 24-week response were analysed; genotypic sensitivity scores (GSS) and weighted-GSS were evaluated.
Virological response was achieved in 74.3% of 105 subjects. Mutations associated with RAL failure were detected in 12/24 subjects with an
integrase genotype, with the prevalence of Q148H + G140S. Each extra unit of GSS (p 0.05, OR 2.62; 95% CI 1.00–6.87). was found to be a
associated with response. Weighted-GSS had borderline statistical signiﬁcance (p 0.063, OR 2.04; 95% CI 0.96–4.33) When stratifying for
different cut-offs (<1 as reference, 1–1.49,  1.5), a borderline signiﬁcant increase in the probability of response appeared for GSS  1.5 (p
0.053, OR 4.00; 95% CI 0.98–16.25). GSS  1 showed the highest sensitivity, 82.6%. Receiver operating characteristic curves depicted the
widest area under the curve (0.663, p 0.054) of GSS  1. Unresponsiveness to RAL-containing regimens among triple-class-experienced
subjects was low. The activity of the background regimen was strongly associated with response. Although few integrase genotypes were
available at failure, half of these were without integrase resistance mutations. The substantial rate of RAL failure in the absence of known
RAL-resistance mutations may be associated with adherence issues and this issue warrants further analysis in longer observations.
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Introduction
The viral integrase (IN) is an important target for treating
human immunodeﬁciency virus type 1 (HIV-1) infection and
preventing clinical progression to AIDS [1]. Raltegravir (RAL)
is the only licensed HIV IN inhibitor so far [2]. It was approved
by the US Food and Drug Administration in October 2007 as
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part of antiretroviral therapy in drug-experienced subjects
with virological failure—e.g. BENCHMRK trials [3]. Due to an
excellent safety proﬁle and potency the use of RAL has been
extended (July 2009) to drug-naive individuals—e.g.
STARTMRK trial [4].
Resistance to RAL has been extensively studied with
regard to major IN resistance and IN polymorphisms in
naive and triple-class experienced subjects [5,6]. As
described by Margeridon-Thermet and Shafer [7], mutations
at nine positions (T66I/A/K, E92Q/V, F121Y, Y143C/R,
P145S, Q146P, S147G, Q148H/R/Q and N155H/S) are
selected by RAL or elvitegravir and reduce susceptibility to
either one or both of these drugs [8,9]. Major signature
mutations associated with RAL failure are Y143R/H/C,
Q148H/K/R, N155H and E92Q. Minor mutations in the
148 pathway are L74M plus E138A, E138K or G140S.
Mutations described in the 155 pathway are L74M, E92Q,
T97A, Y143H, V151I, G163K/R or D232N. The Y143R/H/C
is less common than the other signature mutations. The
Q148K/R is mostly detected after short exposure to RAL,
whereas Y143R/H/C is observed only after prolonged RAL
exposure and usually replaces N155H. A switch from
N155H to Q148H can also occur. An exhaustive list of
mutations in the IN region is: H51Y, T66I/A/K, V72I, L74I/A/
M, E92Q, T97A, T112I, F121Y, T125K, A128T, E138K/A/D,
G140R/C/H, Q146K/P, S147G, Q148K/R/H, V151I, S153Y/A,
M154I, N155S/H, K156N, E157Q, K160D/N, G163R/K,
V165I, V201I, I203M, T206S, S230N/R, V249I, R263K and
C280Y [10]. The most important of these are G140S/A/C
and E138K/A, which increase the ﬁtness of viruses with
Q148H/R/K and lead to high-level resistance to all IN
inhibitors, and T97A, which causes high-level resistance to
RAL in the presence of Y143C/R, although the most
commonly observed is the N155H pathway [11]. Of note,
other than resistance, several factors can inﬂuence the
response to RAL, e.g. adherence, pharmacological proﬁle and
drug–drug interactions. Dolutegravir is a second-generation
IN inhibitor with an increased genetic barrier to resistance
compared with RAL and elvitegravir, which is potentially
useful in subjects experiencing virological failure to RAL or
elvitegravir [12,13]. Further investigations would be useful to
detect the determinants of the virological response to RAL-
containing regimens and the prevalence of IN mutations
associated with RAL failure in clinical practice. With this aim,
we queried the Antiretroviral Resistance Cohort Analysis
(ARCA) resistance database (i) to analyse the virological
response after 24 weeks of a RAL-containing highly active
antiretroviral therapy regimen, (ii) to deﬁne factors associ-
ated with response at week 24, and (iii) to investigate
selection of IN mutations at virological failure.
Materials and Methods
From the ARCA (www.hivarca.net) database, we conducted a
retrospective study and selected 685 RAL-containing regimens
from 526 triple-class-experienced subjects failing their current
treatment and having complete treatment history available.
Our patients failing the RAL-containing regimen did experience
a real viral rebound (two consecutive HIV-RNA determina-
tions above the limit of quantiﬁcation) and the genotypes were
analysed at the time of virological failure when patients were
still taking RAL. Only the initial RAL-containing regimens for
each subject were analysed. The genotypic susceptibility score
(GSS) and weighted-GSS of the RAL-containing regimen were
obtained according to the ARCA built-in algorithm ANTIRET-
ROSCAN [14] and were available for 105/526 subjects. We used
the standard susceptible/intermediate/resistant categorization
for all GSS, as given by the output of the HIVDB WEB-SERVICE
(Stanford HIV drug resistance database. http://hivdb.stanford.
edu/index.html), which were assigned the numerical values of
1.0/0.5/0.0, respectively. Each combination regimen was then
given a GSS based on the sum of the (weighted) scores coded
for the individual drugs included in the regimen. Further
inclusion criteria were (i) detectable HIV-1 RNA at the start of
treatment, (ii) availability of CD4 counts, (iii) HIV reverse
transcriptase (RT)/protease (PRO) genotype within 3 months
before RAL initiation, and (iv) availability of follow-up
HIV-RNA at 24 weeks. Different GSS and weighted-GSS cut-
offs were evaluated for sensitivity, speciﬁcity, positive
predictive value (PPV), negative predictive value (NPV) and
area under the curve (AUC) in a receiver operating charac-
teristic (ROC) curve analysis. Drug resistance mutations were
interpreted following the IAS-USA panel list proposed as
RAL-speciﬁc (www.iasusa.org, update in November 2011)
[15]: L74M, E92Q, T97A, E138A/K, G140S, Y143R/H/C,
Q148H/K/R, V151I, N155H, G163K/R and D232N. The
probability of a virological response at 24 weeks to a RAL-
containing therapy was assessed by means of binary logistic
regression models. From these models we obtained estimates
of relative risks (expressed as OR and 95% CI) for gender, age,
HIV-1 RNA, peak HIV-1 RNA, CD4 cell counts, CD4 cell
nadir, number of RT mutations, and number of PRO
mutations. All of these variables were considered for the
multivariate analysis. Kaplan–Meier curves were designed to
describe the probability of virological success after starting a
RAL-containing regimen. Moreover, we considered the
duration of antiretroviral therapy and the duration of
nucleoside RT inhibitor/non-nucleoside RT inhibitor/protease
inhibitor exposure, GSS (absolute and stratiﬁed), and
weighted-GSS (absolute and stratiﬁed). Different thresholds
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for weighted-GSS and unweighted-GSS were evaluated for
sensitivity, speciﬁcity, PPV, NPV and were plotted on ROC
curves. The two-sided statistical signiﬁcance was set at p 0.05.
SPSS 15 FOR WINDOWS (Chicago, IL, USA) was the statistical
software package used for the analyses.
Results
Descriptive analysis
In all, 105 subjects met all the inclusion criteria. The median
(interquartile range; IQR) antiretroviral exposure at the time
of RAL initiation was 12.3 (IQR 10.0–15.0) years. Virological
response at week 24, deﬁned as HIV-1 RNA <50 copies/mL
was achieved in 78 (74.3%) subjects. Virological failure was
found in 27 subjects and the mean level  standard deviation
of HIV-RNA was 3.4 log10  1.4 copies/mL. At failure of the
RAL-containing regimen, 19 subjects had a further RT/PRO
genotypic test, whereas IN sequences were documented for
24 patients. Table 1 shows the description of subjects with or
without virological control at 24 weeks after RAL initiation.
Analysis of baseline GSS of RAL companion drugs
The GSS of RAL companion drugs, i.e. not including RAL, was
analysed through a 0.25-step stratiﬁcation using ANTIRETRO-
SCAN in 105 subjects with available resistance data (RT+PRO)
at RAL initiation. The majority of the individuals had a GSS of 1
(25.7%); however, 49.5% of the subjects had a GSS  1. The
most frequent protease inhibitor was darunavir, few enfuvir-
tide treatments were observed, and etravirine was present in
around 20% of subjects without a difference in the virological
outcome.
Drug resistance at baseline and at failure
The median number of PRO and RT mutations at failure was
lower than at baseline: 8 (IQR 2–15) versus 11 (IQR 5–16) and
5 (IQR 2–12) versus 8 (IQR 3–11), respectively. As expected,
week-24 non-responders had a higher number of mutations at
failure compared with responders, both in PRO (12; IQR 5–19,
versus 7; IQR 2–13) and RT (9; IQR 3–19, versus 4; IQR 2–10),
without showing any statistical signiﬁcance. Of the 24 RAL-
failing subjects with available IN genotype, 12 (50,0%) did not
show any mutation or just had natural IN polymorphisms
(H51Y, V72I, G140S, K156N, E157Q and V165I). Conversely,
resistance mutations associated with RAL failure were
detected in the other 12 subjects: ﬁve Q148H + G140S
pathway, four N155H pathway, two Y143C/R pathway, and
one subject with mixed Y143R + N155H.
Factors associated with response to RAL-containing therapy
at 24 weeks
Kaplan–Meier estimation showed a 74.3% virological response
after initiating a RAL-containing regimen in the entire cohort.
GSS >1.5 had the highest effect with approximately 85% of a
virological response. In parallel, weighted-GSS >1.5 showed
82% of a virological response compared with other weighted-
GSS strata (Fig. 1a,b).
Univariate analysis (Table 2) revealed an increased proba-
bility of virological response for older subjects: the OR for
each extra-year was 1.09, 95% CI 1.02–1.77 (p 0.016) counts,
whereas nadir CD4, baseline CD4 counts, peak HIV-1 RNA,
and baseline HIV-1 RNA were not associated with virological
suppression. Each extra unit of GSS (p 0.05, OR 2.62; 95% CI
1.00–6.87) was found to be a factor associated with response.
Weighted-GSS had borderline statistical signiﬁcance (p 0.063,
OR 2.04; 95% CI 0.96–4.33). When stratifying for different cut-
offs (<1 as reference, 1–1.49,  1.5), a borderline signiﬁcant
increase in the probability of response appeared for GSS  1.5
(p 0.053, OR 4.00; 95% CI 0.98–16.25).
Multivariate analysis of factors associated with response
Multivariate analysis found an increased probability of virolog-
ical response for every extra-year in our cohort of subjects.
The adjusted OR were between 1.09 and 1.11 when consid-
TABLE 1. Characteristics of subjects with or without virological suppression
HIV-RNA at 24 weeks
Total pDetectable Undetectable
Age Median (IQR) 45.0 (39.5–48.0) 47.0 (42.8–51.5) 46.0 (41.0–51.0) 0.186
ARV exposure in years Median (IQR) 12.7 (8.3–16.0) 12.2 (10.1–15.0) 12.3 (10.0–15.0) 0.872
NNRTI exposure in years Median (IQR) 1.5 (0.9–3.5) 1.7 (1.0–3.3) 1.6 (1.0–3.3) 0.520
NRTI exposure in years Median (IQR) 12.7 (8.3–16.0) 11.9 (10.1–14.8) 12.2 (10.0–14.8) 0.860
PI exposure in years Median (IQR) 9.5 (6.7–11.2) 8.3 (6.2–10.4) 8.4 (6.3–10.6) 0.240
Sex Female N (%) 9 (31.0) 20 (69.0) 29 (100.0) 0.441
Male N (%) 18 (23.7) 58 (76.3) 76 (100.0)
Number of RT mutations Median (IQR) 7.5 (5–11.5) 8 (6–11) 8 (6–11) 0.859
Number of PRO mutations Median (IQR) 13 (10–16.5) 11 (5–14) 11.5 (7–15) 0.140
Total N (%) 27 (25.7) 78 (74.3) 105 (100.0)
ARV, antiretroviral drugs; NNRTI, non-nucleoside reverse transcriptase inhibitors; NRTI, nucleoside reverse transcriptase inhibitors; PI, protease inhibitors; RT, reverse
transcriptase; PRO, protease; Detectable, HIV-RNA  50 copies/mL; Undetectable, HIV-RNA <50 copies/mL.
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ering GSS, weighted-GSS, and different strata of GSS and
weighted-GSS (<1, 1–1.49,  1.5). GSS and weighted-GSS
were associated with virological response with adjusted OR of
4.61 (p 0.05) and 4.20 (p 0.042), respectively. GSS  1.5 was
also associated with an increased degree of response
(Table 2).
Sensitivity, speciﬁcity and ROC curve analyses
The GSS cut-off  1 showed the highest sensitivity, 82.6%, with
speciﬁcity = 50.0%, PPV = 82.6%, NPV = 50.0%, whereas
weighted-GSS cut-off  1.5 had lower sensitivity and speciﬁc-
ity, with PPV = 83.8% and NPV = 40.0%. ROC curves depicted
the widest AUC (0.663, p 0.054) of GSS  1 versus other GSS
cut-offs; weighted-GSS cut-off  1.5 had the widest although
not statistically signiﬁcant AUC (0.649, p 0.081) compared with
the other two weighted-GSS cut-offs (Fig. 2a,b).
Discussion
In this cohort analysis, unresponsiveness to RAL-containing
regimens among multi-failing subjects with a triple-class
experience was relatively low (25.7%). The activity of the
background regimen was a factor associated with response, as
shown by GSS and weighted-GSS. However, it must be noted
that almost half of regimens (49.5%) had a low GSS for RAL
companion drugs. Baseline CD4 counts and baseline HIV-1
RNA were not associated with the virological response. A
(a) (b)
FIG. 1. (a, b) Kaplan–Meier curves describing virological response: (a) genotypic sensitivity score (GSS) estimation; (b) weighted-GSS estimation.
TABLE 2. Factors associated with virological response at 6 months according to univariate and multivariate analyses
p OR [95% CI] p AOR [95% CI] p AOR [95% CI] p AOR [95% CI] p AOR [95% CI]
Age x year 0.016 1.09 [1.02–1.17] 0.044 1.10 [1.00–1.20] 0.047 1.09 [1.00–1.19] 0.036 1.10 [1.01–1.21] 0.028 1.11 [1.01–1.22]
ARV x year 0.427 1.06 [0.92–1.21] 0.617 0.66 [0.13–3.36] 0.737 0.75 [0.15–3.91] 0.481 0.54 [0.09–3.05] 0.581 0.62 [0.11–3.39]
NNRTI x year 0.530 1.10 [0.82–1.49] 0.644 0.90 [0.56–1.43] 0.635 0.89 [0.57–1.42] 0.682 0.91 [0.57–1.44] 0.482 0.85 [0.54–1.34]
NRTI x year 0.312 1.07 [0.94–1.23] 0.485 1.78 [0.35–8.99] 0.579 1.59 [0.31–8.08] 0.393 2.13 [0.37–12.12] 0.461 1.89 [0.35–10.22]
PI x year 0.440 0.94 [0.80–1.10] 0.267 0.85 [0.64–1.13] 0.172 0.82 [0.61–1.09] 0.431 0.89 [0.68–1.18] 0.343 0.88 [0.67–1.15]
Sex Male 0.981 0.99 [0.30–3.21] 0.612 1.46 [0.33–6.40] 0.633 1.43 [0.33–6.21] 0.680 1.36 [0.32–5.83] 0.827 1.17 [0.28–4.94]
CD4 x10 unit 0.686 1.00 [0.98–1.03] 0.677 0.99 [0.96–1.02] 0.671 0.99 [0.96–1.02] 0.384 0.99 [0.96–1.02] 0.390 0.99 [0.96–1.02]
Nadir CD4 x10 unit 0.106 1.05 [0.99–1.13] 0.392 1.04 [0.95–1.13] 0.395 1.04 [0.95–1.13] 0.272 1.05 [0.96–1.14] 0.311 1.04 [0.96–1.13]
Log VL x unit 0.092 0.59 [0.31–1.09] 0.102 0.46 [0.18–1.17] 0.082 0.43 [0.17–1.11] 0.097 0.46 [0.18–1.15] 0.075 0.43 [0.17–1.09]
Log peak VL x unit 0.456 0.72 [0.31–1.70] 0.180 2.75 [0.63–12.02] 0.181 2.68 [0.63–11.33] 0.143 3.07 [0.68–13.8] 0.175 2.66 [0.65–10.9]
N Mutations PR x unit 0.481 0.97 [0.88–1.06] 0.959 1.00 [0.84–1.19] 0.633 1.05 [0.87–1.27] 0.977 1.00 [0.84–1.20] 0.906 1.01 [0.84–1.21]
N Mutations RT x unit 0.300 1.07 [0.94–1.21] 0.286 1.12 [0.91–1.36] 0.274 1.12 [0.91–1.37] 0.318 1.11 [0.90–1.38] 0.314 1.11 [0.90–1.38]
GSS x unit 0.050 2.62 [1.00–6.87] 0.050 4.61 [1.00–21.21]
GSS Weighted x unit 0.063 2.04 [0.96–4.33] 0.042 4.20 [1.06–16.71]
GSS <1 0.108 1 1
1–1.49 0.101 2.91 [0.81–10.43] 0.097 4.62 [0.76–28.12]
 1.50 0.053 4.00 [0.98–16.25] 0.045 8.00 [1.05–61.21]
GSS Weighted <1 0.270 1 1
1–1.49 0.606 1.50 [0.32–6.99] 0.767 1.38 [0.16–11.66]
 1.50 0.115 2.77 [0.78–9.86] 0.098 6.06 [0.72–51.34]
Virological response was obtained in 74.3% of subjects. Statistically signiﬁcant p values are shown in italics. ARV, antiretroviral drugs; NNRTI, non-nucleoside reverse transcriptase
inhibitors; NRTI, nucleoside reverse transcriptase inhibitors; PI, protease inhibitors; VL, viral load; N, number; GSS, genotypic susceptibility score; AOR, adjusted odds ratio.
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 19, 936–942
CMI Rusconi et al. Response to RAL in a large resistance database 939
possible explanation of this ﬁnding is the different setting of
clinical trials, e.g. BENCHMRK and STARTMRK, compared
with cohort observational studies. One possible explanation of
the statistical association between age and response to therapy
is that older patients in our cohort were more adherent (both
in dosing and timing) to treatment.
Although few IN genotypes were available at failure, notably
half of these cases were without IN resistance mutations.
Finding IN mutations in approximately half of the successfully
genotyped subjects has been very common in most RAL trials,
both in naive subjects (STARTMRK, QDMRK [16]) and
experienced subjects (SWITCHMRK [17], BENCHMRK). This
ﬁnding represents a common underlying driving force in all
virological failures. The relationship between adherence levels
and the risk of development of resistance is differently shaped
with different drug classes and can be explained by drug
pharmacokinetics and ﬁtness costs of resistant virus [18]. The
relatively low genetic barrier of RAL suggests the need for
optimal regimen adherence to obtain virological success.
Hatano et al. [19] did not conﬁrm this assumption: the self-
reported adherence rate to antiretroviral use was 97.8% in
subjects with virological success, 98.7% in subjects who failed
with IN resistance, and 90.7% in subjects who failed with wild-
type virus. All differences appeared signiﬁcant even when the
analysis was limited to adherence to IN inhibitors. Failure with
wild-type IN at 90% and adherence below optimal levels may
explain the high frequency of this ﬁnding in our study as well as
in clinical trials [20].
The relationship between GSS and treatment outcomes was
analysed in a recent report by the research group in Stanford and
by the ARCA database [14,21]. Moreover, a recent paper by
Malet et al. [22] demonstrated that a GSS <2 in the current
antiretroviral regimen and HIV-RNA >200 copies/mL at failure
were independently associated with the development of RAL
resistance. Using ten-fold cross-validation, the averaged area
under the ROC curve for all algorithms increased from 0.76 with
unweighted regimen genotypic sensitivity score (rGSS) to 0.80
with weighted rGSS. In our study, each extra unit of GSS and
weighted-GSS was associated with a higher probability of
response, the level needed for virological success being  1.5
forGSS. In parallel,GSS cut-off  1 showed thehighest sensitivity
as pointed out by ROC curve analysis. In our study, the decrease
in themedian number of PROandRTmutations at failurewas not
signiﬁcant and could be related to genetic adaptation driven by
ﬁtness issues following treatment switch or to adherence issues.
The availability of compounds, such as RAL, belonging to
new drug classes is crucial for achieving virological success in
patients harbouring extensively drug-resistant viruses. Zaccar-
elli et al. [23] described no signiﬁcant association between
extended resistance and HIV progression in patients who failed
between 2004 and 2008, contrary to what happened to
patients who failed between 1999 and 2003. In our study, IN
resistance analysis is underestimated because of at least two
caveats. First, a potential role of compensatory mutations
could not be analysed in the absence of a baseline IN genotype.
Second, analysis of the IN genotype was not always performed
at failure. Other studies showed the appearance of these
mutations at virological failure or at viral rebound following
RAL withdrawal [24]. On the other hand, no major IN
mutation had been detected by standard sequencing in
IN-naive subjects [25], although RAL-resistant minority species
could be present before RAL therapy [26–29].
(a) (b)
FIG. 2. (a, b) Receiver operating characteristic (ROC) curve analyses for (a) genotypic sensitivity score (GSS) and (b) weighted-GSS (W-GSS). Both
scores were evaluated at different cut-offs (1, 1.5, and 2).
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Unresponsiveness to RAL-containing regimens among sub-
jects with a triple-class experience was relatively low in this
cohort analysis. The activity of the background regimen was
strongly associated with response as shown by GSS and less so
by weighted-GSS. The substantial rate of RAL failure in the
absence of known RAL-resistance mutations may be associ-
ated with adherence issues and this issue warrants further
analysis in longer observations.
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